AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9166304 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-g single oral dose of metronidazole
Number of subjects: 164
Study 1529296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator without an arterial line filter (Group I)
Number of subjects: 92
Study 1529296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble oxygenator with a filter (Group II)
Number of subjects: 92
Study 1529296 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat‐sheet membrane oxygenator without a filter (Group III)
Number of subjects: 92
Study 3908603 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine treatment before suture
Number of subjects: 418
Study 3908603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no povidone iodine treatment)
Number of subjects: 418
Study 3908603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined trials including povidone iodine treatment
Number of subjects: 418
Study 31300577 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐cigarettes
Number of subjects: 150
Study 31300577 — intervention group
Group type: COMPARATOR
Intervention: nicotine gum
Number of subjects: 150
Study 29393182 — intervention group
Group type: EXPERIMENTAL
Intervention: Procarbazine, CCNU, and vincristine (PCV) chemotherapy plus fractionated radiotherapy (FRT)
Number of subjects: 0
Study 29393182 — intervention group
Group type: COMPARATOR
Intervention: Fractionated radiotherapy (FRT) alone
Number of subjects: 0
Study 29393182 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Number of subjects: 0
Study 27277946 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multi-nutrient supplement (omega-3 fatty acids, calcium, selenium, B-11 vitamin, D-3 vitamin)
Number of subjects: 1000
Study 27277946 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-related behavioral change therapy (FBC)
Number of subjects: 1000
Study 27277946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 27277946 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1000
Study 27277946 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement and FBC therapy
Number of subjects: 1000
Study 27277946 — intervention group
Group type: COMPARATOR
Intervention: Placebo and usual care
Number of subjects: 1000
Study 25512294 — intervention group
Group type: EXPERIMENTAL
Intervention: Midpalatal mini-implant anchorage system
Number of subjects: 14
Study 25512294 — intervention group
Group type: COMPARATOR
Intervention: Fixed appliance treatment with midpalatal mini-implant
Number of subjects: 14
Study 22382876 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA + GM-CSF
Number of subjects: 24
Study 22382876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose of CEA
Number of subjects: 24
Study 22382876 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CEA IgA antibodies
Number of subjects: 24
Study 22382876 — intervention group
Group type: EXPERIMENTAL
Intervention: High IgA anti-CEA titers
Number of subjects: 24
Study 20646560 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 1212
Study 20646560 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 1212
Study 17765378 — intervention group
Group type: EXPERIMENTAL
Intervention: yi‐gan san (YGS) at an average daily dosage of 6.4+/‐1.9 g (2.5‐7.5 g)
Number of subjects: 20
Study 11372590 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9*2 mutation
Number of subjects: 157
Study 11372590 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9*3 mutation
Number of subjects: 157
Study 11372590 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C9 metabolism
Number of subjects: 157
Study 9760288 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab
Number of subjects: 1265
Study 9760288 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1265
Study 7921530 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate inhalation aerosol via collapsible spacer
Number of subjects: 55
Study 7921530 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate inhalation aerosol via traditional large volume spacer
Number of subjects: 55
Study 7921530 — intervention group
Group type: EXPERIMENTAL
Intervention: Collapsible spacer
Number of subjects: 55
Study 7921530 — intervention group
Group type: COMPARATOR
Intervention: Traditional large volume spacer
Number of subjects: 55
Study 2457710 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled subcutaneous injections (PCIs) of hydromorphone (HM)
Number of subjects: 25
Study 2457710 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous infusion (CSCI) of hydromorphone (HM)
Number of subjects: 25
Study 31161726 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise cold-water immersion (CWI) at 8°C
Number of subjects: 9
Study 31161726 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CON)
Number of subjects: 9
Study 31161726 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-exercise cold-water immersion (CWI) LOW
Number of subjects: 9
Study 28562279 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma intervention tailored to allergen sensitivity and exposure, comprising 4 visits over 1 year.
Number of subjects: 590
Study 28562279 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 590
Study 25935877 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg when <50 kg, 100 mg otherwise)
Number of subjects: 303
Study 25935877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 24283598 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (CCB)
Number of subjects: 0
Study 24283598 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (ACE-inhibitor)
Number of subjects: 0
Study 24283598 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (prior to first GI hemorrhage)
Number of subjects: 0
Study 21737829 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 1 ml of 5% hypertonic saline into biceps causing muscle pain (pain rating ∼5 on a scale from 0 to 10)
Number of subjects: 13
Study 21737829 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 1 ml of 5% hypertonic saline into biceps causing muscle pain
Number of subjects: 13
Study 19194214 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated High Dose (CHD, 6.66‐7.4 MBq/g)
Number of subjects: 97
Study 19194214 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated Low Dose (CLD, 3.33‐3.70 MBq/g)
Number of subjects: 97
Study 19194214 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed High Dose (FHD, 832 MBq)
Number of subjects: 97
Study 19194214 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed Low Dose (FLD, 481 MBq)
Number of subjects: 97
Study 16489077 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (0.1, 0.3, 1.0, or 3.0 mg/kg s.c.)
Number of subjects: 54
Study 16489077 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (90 mg i.v.)
Number of subjects: 54
Study 15109923 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive, brief episodes of isocapnic hypoxia (6% O(2) in N(2), 60s)
Number of subjects: 10
Study 15109923 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid chemoreceptor stimulation in vagotomized anesthetized cats
Number of subjects: 10
Study 10908095 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 0
Study 9075106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic frequency (PEMF) therapy combined with Birmingham Containment Splint
Number of subjects: 21
Study 9075106 — intervention group
Group type: COMPARATOR
Intervention: Inactive treatment coil (Control group)
Number of subjects: 21
Study 8372952 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated bed nets
Number of subjects: 0
Study 8372952 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-impregnated curtains
Number of subjects: 0
Study 8372952 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30957602 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniopatch
Number of subjects: 100
Study 30957602 — intervention group
Group type: COMPARATOR
Intervention: Routine management (Control)
Number of subjects: 100
Study 31071734 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 IU weekly for 3 months)
Number of subjects: 42
Study 31071734 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo pearls weekly for 3 months)
Number of subjects: 42
Study 28459966 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin (200 mg loading dose on day 1, followed by 100 mg once daily)
Number of subjects: 539
Study 25465932 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFAs (4 g/day)
Number of subjects: 190
Study 25465932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 24469141 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL)
Number of subjects: 41
Study 24469141 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching
Number of subjects: 41
Study 21281532 — intervention group
Group type: EXPERIMENTAL
Intervention: High Calcium and High Fat (HC/HF) diet
Number of subjects: 9
Study 21281532 — intervention group
Group type: EXPERIMENTAL
Intervention: High Fat (HF) diet
Number of subjects: 9
Study 21281532 — intervention group
Group type: EXPERIMENTAL
Intervention: High Calcium (HC) diet
Number of subjects: 9
Study 19636008 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus erlotinib for 8 weeks
Number of subjects: 52
Study 19636008 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab alone for 8 weeks
Number of subjects: 52
Study 19636008 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab therapy (presurgical treatment)
Number of subjects: 52
Study 16799819 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm cranking (ARM) training, 12-week, 30 min, 3 times/week
Number of subjects: 12
Study 16799819 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloergometer (CYC) training, 12-week, 30 min, 3 times/week
Number of subjects: 12
Study 16799819 — intervention group
Group type: COMPARATOR
Intervention: Control group (C), no training
Number of subjects: 12
Study 15465937 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing examples of situations where patient identification may be important
Number of subjects: 1411
Study 15465937 — intervention group
Group type: COMPARATOR
Intervention: Identification bracelet with patient name
Number of subjects: 1411
Study 15465937 — intervention group
Group type: COMPARATOR
Intervention: Identification bracelet with anonymous code
Number of subjects: 1411
Study 11295009 — intervention group
Group type: EXPERIMENTAL
Intervention: IFT spinal nerve and The Back Book
Number of subjects: 60
Study 11295009 — intervention group
Group type: EXPERIMENTAL
Intervention: IFT painful area and The Back Book
Number of subjects: 60
Study 11295009 — intervention group
Group type: COMPARATOR
Intervention: Control (The Back Book only)
Number of subjects: 60
Study 9309980 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms b.i.d.
Number of subjects: 67
Study 9309980 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone 200 micrograms b.i.d.
Number of subjects: 67
Study 8149186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid bag height at 60-65 cm
Number of subjects: 550
Study 8149186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid bag height at 70-75 cm
Number of subjects: 550
Study 8149186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid bag height at 80-85 cm
Number of subjects: 550
Study 8149186 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid bag height at 90-100 cm
Number of subjects: 550
Study 3759474 — intervention group
Group type: COMPARATOR
Intervention: HMO
Number of subjects: 2023
Study 3759474 — intervention group
Group type: EXPERIMENTAL
Intervention: FFS
Number of subjects: 2023
Study 3759474 — intervention group
Group type: EXPERIMENTAL
Intervention: HMO vs FFS
Number of subjects: 2023
Study 31997482 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction blister roofs
Number of subjects: 40
Study 31997482 — intervention group
Group type: COMPARATOR
Intervention: Partial-thickness epidermal cuts
Number of subjects: 40
Study 28793816 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness material addressing suicide myths
Number of subjects: 0
Study 26927433 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrodilatation (HD)
Number of subjects: 86
Study 26927433 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular injection
Number of subjects: 86
Study 26927433 — intervention group
Group type: COMPARATOR
Intervention: Subacromial injection
Number of subjects: 86
Study 25232371 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 88
Study 25232371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 22738442 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV)
Number of subjects: 46
Study 22738442 — intervention group
Group type: COMPARATOR
Intervention: Conventional Assist/Control (A/C)
Number of subjects: 46
Study 20934459 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV (Japanese encephalitis chimeric virus vaccine)
Number of subjects: 2011
Study 20934459 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV
Number of subjects: 2011
Study 20934459 — intervention group
Group type: COMPARATOR
Intervention: MBD-JE (mouse brain-derived vaccine)
Number of subjects: 2011
Study 20934459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2011
Study 18579693 — intervention group
Group type: EXPERIMENTAL
Intervention: meCS6 alone (1 mg)
Number of subjects: 60
Study 18579693 — intervention group
Group type: EXPERIMENTAL
Intervention: meCS6 with adjuvant (2 microg of LT(R192G))
Number of subjects: 60
Study 16040211 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg plus MPA 2.5 mg daily orally for 12 months (hypertensive HRT group)
Number of subjects: 62
Study 16040211 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg plus MPA 2.5 mg daily orally for 12 months (normotensive HRT group)
Number of subjects: 62
Study 16040211 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypertensive control)
Number of subjects: 62
Study 16040211 — intervention group
Group type: COMPARATOR
Intervention: Control group (normotensive control)
Number of subjects: 62
Study 12924641 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate alone
Number of subjects: 0
Study 10442441 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract PN246 (Bio‐Biloba)
Number of subjects: 27
Study 10442441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8763369 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic ear drops used for five days after grommet insertion
Number of subjects: 0
Study 8763369 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotic ear drops
Number of subjects: 0
Study 2054279 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin with labetalol
Number of subjects: 26
Study 2054279 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac with labetalol
Number of subjects: 26
Study 2054279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 6354007 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulfate aerosol (two sprays, four times a day for 14 weeks)
Number of subjects: 50
Study 6354007 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol sulfate aerosol (two sprays, four times a day for 14 weeks)
Number of subjects: 50
Study 30806102 — intervention group
Group type: EXPERIMENTAL
Intervention: CC plus metformin and L-carnitine
Number of subjects: 274
Study 30806102 — intervention group
Group type: COMPARATOR
Intervention: CC plus metformin and placebo
Number of subjects: 274
Study 30806102 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 274
Study 30806102 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine group
Number of subjects: 274
Study 30379308 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg of astaxanthin (ASTX)
Number of subjects: 32
Study 30379308 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 gr of dark chocolate (DC)
Number of subjects: 32
Study 30379308 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 gr of DC and 7 mg of ASTX ingested simultaneously
Number of subjects: 32
Study 30379308 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 gr of a lycosomal formulation of DC containing 7 mg of co‐crystalized ASTX (L‐DC‐ASTX)
Number of subjects: 32
Study 26912206 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit & Vaardig op School (F&V) intervention for 2 years, 22 weeks per year, 3 times a week
Number of subjects: 499
Study 26912206 — intervention group
Group type: COMPARATOR
Intervention: Regular classroom lessons
Number of subjects: 499
Study 25311554 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended follow-up in the HF clinic (n = 461)
Number of subjects: 921
Study 25311554 — intervention group
Group type: COMPARATOR
Intervention: Discharge to primary care (n = 460)
Number of subjects: 921
Study 22931259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation therapy
Number of subjects: 1386
Study 22931259 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation therapy
Number of subjects: 1386
Study 20673857 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Proprioceptive Neuromuscular Facilitation (PNF) stretching
Number of subjects: 30
Study 20673857 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial Trigger Point (MTrP) therapy plus modified PNF stretching
Number of subjects: 30
Study 20673857 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no treatment
Number of subjects: 30
Study 18173917 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 1526
Study 18173917 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 1526
Study 15468166 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous androgen ablation after 14 months of protocol treatment
Number of subjects: 215
Study 15468166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen ablation after 14 months of protocol treatment
Number of subjects: 215
Study 15468166 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of LHRH agonist with short-term antiandrogen treatment for flare-up prevention
Number of subjects: 215
Study 11935714 — intervention group
Group type: EXPERIMENTAL
Intervention: Proper instruction in practical management of diabetes; continuous education and encouragement of parents and children.
Number of subjects: 0
Study 11935714 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher target blood glucose levels for preschool children.
Number of subjects: 0
Study 11935714 — intervention group
Group type: EXPERIMENTAL
Intervention: Management by pediatric diabetes care teams and family physicians.
Number of subjects: 0
Study 10512167 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive regimens including bone marrow transplantation (BMT)
Number of subjects: 27
Study 10512167 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT) after achieving remission
Number of subjects: 27
Study 10512167 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation (BMT)
Number of subjects: 27
Study 10512167 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 27
Study 8961038 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine in addition to supportive psychotherapy
Number of subjects: 50
Study 8961038 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin in addition to supportive psychotherapy
Number of subjects: 50
Study 8961038 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Number of subjects: 50
Study 8961038 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic treatment conditions
Number of subjects: 50
Study 8961038 — intervention group
Group type: COMPARATOR
Intervention: Baseline illness-related social impairment
Number of subjects: 50
Study 1743318 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral progesterone (200 mg)
Number of subjects: 10
Study 1743318 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (400 mg pessary)
Number of subjects: 10
Study 1743318 — intervention group
Group type: COMPARATOR
Intervention: Both formulations (oral and vaginal)
Number of subjects: 10
Study 6812003 — intervention group
Group type: EXPERIMENTAL
Intervention: Pristinamycin (2-3 g/d)
Number of subjects: 82
Study 6812003 — intervention group
Group type: COMPARATOR
Intervention: Oxacillin (4-6 g/d)
Number of subjects: 82
Study 30640664 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery Protocol (ERP)
Number of subjects: 36
Study 30640664 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (preprotocol)
Number of subjects: 36
Study 28052799 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol MDPI 90 μg per inhalation, two inhalations four times daily (total daily dose, 720 μg)
Number of subjects: 184
Study 28052799 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDPI
Number of subjects: 184
Study 26484517 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized vestibular rehabilitation (8 weeks)
Number of subjects: 40
Study 26484517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 23893140 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental stabilization training
Number of subjects: 30
Study 23893140 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Number of subjects: 30
Study 23893140 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 20943753 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electro-acupuncture (EA)
Number of subjects: 84
Study 20943753 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise
Number of subjects: 84
Study 20943753 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 84
Study 19620163 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-management
Number of subjects: 200